Latest News

Request for proposals (RfP) for selection of new manufacturer(s) for development and commercialization of affordable Rifapentine-based formulations

Approximately, 1.7 billion individuals were latently infected with tuberculosis in 2014, just under a quarter of the global population. Among the latently infected population, people living with HIV and children under 5 who are household contacts of bacteriologically-confirmed pulmonary TB cases, are at a higher risk of progressing from latent infection to active disease. In 2016, the World Health Organization reported that 1.3 million people living with HIV and 160,000 children under 5 were started on TB preventive therapy globally. With newly available shorter Rifapentine (RPT)-based regimens, uptake is expected to continue to increase significantly over the next 5 years. (more…)

Statement on UN High-Level Meeting on TB

When it comes to preventing TB, we can and must do better
Statement by Gavin Churchyard, CEO of Aurum Institute

We’ve known how to prevent and treat TB for over 70 years. Yet, in 2017 an estimated 10 million people fell ill from the disease, and every day more than 4,000 people die from TB. Many of these deaths can be prevented. Almost a quarter of the globe is infected with the bacteria that causes tuberculosis (TB). People with latent TB infection have no symptoms, are not contagious and most of them don’t know they’re infected—but they are at risk of developing TB disease at some point in their life. (more…)

Good news! The first IMPAACT4TB newsletter is out!

IMPAACT4TB is a four-year project introducing a new way to tackle latent TB infection — the seed bed of TB—in order to slow and ultimately stop the flood of new TB cases occurring every year.

(more…)